Sermorelin vs Tesamorelin
Sermorelin (GHRH 1-29 analogue)
A GHRH fragment historically approved as a diagnostic and pediatric GH agent, now used in compounded anti-aging research.
Tesamorelin (stabilized GHRH analogue)
An FDA-approved GHRH analogue that reduces visceral fat, now also studied for cognition in older adults at Alzheimer's risk.
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA status | Previously FDA-approved (Geref, discontinued); available compounded | FDA-approved (Egrifta) for HIV-associated lipodystrophy |
| Half-life | ~10-20 minutes | ~26-38 minutes |
| Molecular weight | 3,357.9 Da | 5,135.9 Da |
| Mechanism | Activates pituitary GHRH receptors to stimulate physiological growth hormone release. | Activates pituitary GHRH receptors to stimulate physiological, pulsatile growth hormone release, preserving hypothalamic feedback. |
| Legal status (US) | Prior approval discontinued; available via compounding pharmacies | FDA-approved for a specific indication, prescription only |
Frequently asked questions
What is the difference between Sermorelin and Tesamorelin?
Sermorelin: A GHRH fragment historically approved as a diagnostic and pediatric GH agent, now used in compounded anti-aging research. Tesamorelin: An FDA-approved GHRH analogue that reduces visceral fat, now also studied for cognition in older adults at Alzheimer's risk.
Which has stronger research evidence, Sermorelin or Tesamorelin?
Sermorelin is rated Moderate and Tesamorelin is rated Strong for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are Sermorelin and Tesamorelin FDA-approved?
Sermorelin: Previously FDA-approved (Geref, discontinued); available compounded. Tesamorelin: FDA-approved (Egrifta) for HIV-associated lipodystrophy.
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.